# A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

> **NCT02021474** · PHASE2 · UNKNOWN · sponsor: **AgoneX Biopharmaceuticals, Inc.** · enrollment: 130 (estimated)

## Conditions studied

- Migraine Prophylaxis

## Interventions

- **DRUG:** AGX-201
- **DRUG:** Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).

## Key facts

- **NCT ID:** NCT02021474
- **Lead sponsor:** AgoneX Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2023-07
- **Final completion:** 2023-07
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021474, "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02021474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*